AHRQ seeks public input on HIE

The Agency for Healthcare Research and Quality (AHRQ) is seeking scientific data from the public in inform its systematic review of health information exchange, which currently is being conducted by the evidence-based practice centers for the AHRQ Effective Health Care Program.

Key questions posed to stakeholders include:

  • Is HIE effective in improving clinical, economic and population outcomes?
  • What harms have resulted from HIE?
  • Is HIE effective in improving intermediate outcomes such as patient and provider experience, perceptions or behavior; healthcare processes; or the availability, completeness of accuracy of information?
  • What is the current level of use and primary uses of HIE?
  • How does the usability of HIE impact effectiveness or harms for individuals and organizations?
  • What facilitators and barriers impact implementation of HIE?
  • What factors influence sustainability of HIE?

Comments are due by Sept. 29. See the Federal Register notice for more information.

 

 

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.